
Finasteride, best known as the enlarged-prostate medicine Proscar, is a safe, effective way to reduce the risk of prostate cancer, according to long-term findings from the Prostate Cancer Prevention Trial (PCPT). The trial was funded by the U.S. National Cancer Institute and enrolled nearly 19,000 men between 1993 and 1997. Initially it found that finasteride — a hormone-blocking drug — cut the risk of prostate cancer by 25 percent. Those results were published in 2003. The newly released long-term data show that the reduction of prostate cancer risk has continued and that fewer than 100 men in the trial died from prostate cancer in more than two decades of follow-up, according to a research team led by Dr. Ian Thompson. The updated results also showed no statistically significant increased risk of death from prostate cancer among men taking finasteride. This removes concerns over early findings of a possible risk of more aggressive cancers among patients who take the drug. “Finasteride is safe, inexpensive and effective as a preventive strategy for prostate cancer,” said Thompson, who is principal investigator of the PCPT for the SWOG Cancer Research Network. The SWOG Cancer Research Network is an international cancer clinical trials group. “Doctors should share these results with men who get regular prostate-specific antigen [PSA] tests that screen for the presence of prostate cancer,” Thompson said in a… read on >